Clene Inc.
CNM-Au8
amyotrophic lateral sclerosis (ALS)
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for CNM-Au8 in amyotrophic lateral sclerosis (ALS) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The Company is conducting the Phase 3 confirmatory study for CNM-Au8, which it intends to commence in the first quarter of 2027.”